Gain Therapeutics to Participate in Upcoming Investor Conferences

Core Insights - Gain Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing next-generation allosteric small molecule therapies [2][3] - The company’s lead drug candidate, GT-02287, is currently in a Phase 1b clinical trial for treating Parkinson's disease and has potential applications in other neurodegenerative diseases [2][3] Company Overview - Gain Therapeutics is pioneering the discovery of allosteric therapies, utilizing its advanced Magellan™ platform to accelerate drug discovery [3] - The company is also developing multiple undisclosed preclinical assets targeting lysosomal storage disorders, metabolic diseases, and solid tumors [2] Upcoming Events - Gene Mack, President and CEO, will present at the BIO 2025 conference on June 18, 2025, at 1:45 p.m. EST [1] - Additionally, Gene Mack will participate in a virtual fireside chat at the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference on June 17, 2025, at 7:00 a.m. EST [5]